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LMP1 induces the phenotypic transformation of fibroblasts and affects regulators of the cell cycle during this
process. LMP1 decreases expression of the cyclin-dependent kinase inhibitor p27 and increases the levels and
phosphorylation of cyclin-dependent kinase 2 and the retinoblastoma protein. In the present study, the effects
of LMP1 on cell cycle progression and the mechanism of p27 downregulation by LMP1 were determined.
Although p27 is frequently regulated at the posttranscriptional level during cell cycle progression and in
cancer, LMP1 did not decrease ectopically expressed p27. However, LMP1 did decrease p27 RNA levels and
inhibited the activity of p27 promoter reporters. The LMP1-regulated promoter element was mapped to a
region containing two E2F sites. Electrophoretic mobility shift assays determined that the regulated cis element
bound an inhibitory E2F complex containing E2F4 and p130. These findings indicate that LMP1 decreases p27
transcription through effects on E2F family transcription factors. This property likely contributes to the ability
of LMP1 to stimulate cell cycle progression.
Epstein-Barr virus (EBV) is a herpesvirus that causes infec-
tious mononucleosis and is associated with a number of ma-
lignancies. EBV infection of B cells results in a latent infection
and the transformation of B cells in vitro and in vivo. Several
proteins are required for EBV-mediated B-cell transforma-
tion, including the EBV nuclear antigens (EBNAs), EBNA1,
EBNA2, EBNA3A, and EBNA3C, and latent membrane pro-
tein 1 (LMP1). LMP1 is expressed in most EBV-associated
cancers and is considered the EBV oncogene as it is able to
induce fibroblast transformation (34, 60, 83, 84). Expression of
LMP1 is frequently detected in nasopharyngeal carcinoma,
and LMP1 induces phenotypic changes in epithelial cells and
nasopharyngeal carcinoma cell lines, including increased mo-
tility, invasion, and migration (12, 45, 60, 66, 73).
LMP1 is a constitutively active tumor necrosis factor recep-
tor homologue. The transmembrane domain of LMP1 medi-
ates self-association in the absence of ligand, and LMP1 is
recruited to cholesterol-rich lipid raft domains in the mem-
brane (3, 14, 20, 28, 58, 81). LMP1 initiates signaling from two
carboxyl-terminal activating regions (CTAR1 and CTAR2) by
recruiting tumor necrosis factor receptor-associated factors
(TRAFs) and other adaptors (33). LMP1 induces constitutive
signaling of nuclear factor B (NF-B), phosphatidylinositol
3-kinase (PI3K), mitogen-activated protein kinase (MAPK),
and c-Jun N-terminal kinase (11, 16, 31, 43, 44, 52, 56, 61, 71).
Signaling from CTAR1 is required for EBV B-cell transfor-
mation and for LMP1 fibroblast transformation (5, 30, 32, 53,
78). CTAR1 uniquely activates several pathways and proteins
and induces both canonical and noncanonical NF-B, PI3K,
and MAPK signaling. Several growth-stimulating proteins up-
regulated by CTAR1 have been identified, including the epi-
dermal growth factor receptor, TRAF1, and inhibitors of dif-
ferentiation 1 (Id1) and Id3 (13, 18, 51). LMP1 induces the
transcription of the epidermal growth factor receptor, and this
property is dependent upon activation of a specific NF-B
complex containing Bcl-3 and dependent upon STAT3 activa-
tion (39, 72). The contribution of distinct signaling pathways to
fibroblast transformation has been analyzed using a combina-
tion of LMP1 CTAR1 mutants and chemical inhibitors. Trans-
formation of fibroblasts required activation of the MAPK–
extracellular signal-regulated kinase (ERK) pathways and
PI3K, and inhibition of these pathways blocked transformation
(44). Inhibition of ERK blocked LMP1-induced epithelial cell
motility and invasion (12). In contrast, pharmacological inhi-
bition of NF-B had minimal effects while inhibition of the
expression of Id1 with small interfering RNA slightly impaired
the growth of transformed fibroblasts (17, 43). PI3K activation
correlated with the regulation of a number of cell cycle pro-
teins associated with G1/S transition (18, 43, 44). During ro-
dent and human fibroblast transformation, LMP1 decreases
the levels of the cyclin-dependent kinase inhibitor (CDKI) p27,
which binds and inhibits the activity of CDK/cyclin complexes
to arrest cell cycle progression. (17, 18, 43–45). The trans-
formed cells also contain increased activated cyclin-dependent
kinase 2 (Cdk2) and the phosphorylated inactivated form of
retinoblastoma (Rb). Lymphomas of transgenic mice engi-
neered to express LMP1 also have low levels of p27 protein
(65), and p27 upregulation is associated with the growth arrest
of EBV-positive lymphocyte cell lines (85, 86). Because of their
potent growth-inhibitory activity, many cancers have devel-
oped mechanisms to downregulate or inactivate the CDKIs (2,
4, 76).
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In the current study the mechanism of regulation of p27 by
LMP1 was determined. LMP1 and several LMP1 mutants re-
duced p27 protein expression in Rat-1 cells. However, this did
not reflect posttranscriptional regulation of p27, as ectopically
expressed p27 was not reduced by LMP1. LMP1 greatly re-
duced p27KIP1 RNA levels and decreased the activity of
p27KIP1 promoter reporters. The cis element regulated by
LMP1 was mapped to 900 bp of the promoter that contained
E2F consensus sites. According to the results of electro-
phoretic mobility shift assays (EMSAs), LMP1 affected the
migration patterns of probes containing the E2F site, and an-
tibodies for E2F4 and p130 induced new complexes. These
data indicate that p27 transcription is regulated by E2F-depen-
dent transcription and that LMP1 induces formation of inhib-
itory E2F4 and p130-containing complexes. These effects of
LMP1 on E2F/pocket proteins likely contribute to the LMP1-
mediated stimulation of cell cycle progression. The findings of
this study identify reciprocal regulation between p27 and E2F:
decreased p27 can increase CDK activity and E2F-dependent
transcription and E2F transcription factors can inhibit p27
expression.
MATERIALS AND METHODS
Plasmids. The cloning of wild-type and mutant LMP1 into retrovirus packag-
ing vector pBabe was previously described (18, 44). LMP1 mutants used in the
current study include LMP1-A5 (CTAR1 mutant, TRAF binding domain
[P204xQ206xT208] changed to all alanines [A5]), 1-220 (amino acids 1 to 220,
CTAR2 deleted), and 1-220-A5 (CTAR1 mutated/CTAR2 deleted).
The cloning of the rat p27KIP1/cyclin-dependent kinase inhibitor 1B gene for
specific RNase protection probes was previously described (17). The myc-tagged
p27 expression vector, M3-p27, was generated in the same way as the RNase
protection probe plasmid except that it was inserted downstream of the triple
myc tag of M3-pcDNA3 (40).
The cloning of the full-length p27 promoter reporter construct p27-1501
containing upstream regulatory sequence of p27KIP1/cyclin-dependent kinase
inhibitor 1B of Rattus norvegicus was previously described (17). Truncations at
the 5 end of the promoter were constructed using convenient restriction
enzyme sites, p27-1066 (BamHI), p27-939 (SacI), and p27-554 (SacI). Puta-
tive transcription factor binding sites were determined within the region from
939 to 554 using the online programs TFSEARCH (http://www.cbrc.jp
/research/db/TFSEARCH.html) (27) and MotifMogul (http://xerad
.systemsbiology.net/MotifMogulServer/) (24). Internal deletions within the re-
gion from 939 to 554 were created by full-length plasmid PCR mutagenesis
with AccuPrime Pfx DNA polymerase (Invitrogen) according to the manufac-
turer’s directions using 5-phosphorylated primers. A putative FoxA1/3 site was
deleted using Foxp27-744 (GCTAGCCAGAGCAGGTTTGTTGGCAGTCG)
and Foxp27-777 (CAAACGGCCGGAGAGCTGGGG) to create 740-774. A
putative MZF1 site was deleted using MZF1p27-788 (CCGTTTGGCTAGTT
TGTTTGTCTTATTTTTAATTTCTCCGGGGCCAG) and MZF1p27-812 (C
CGCGGCCAGGCGGAGACCCGGGAATCTAG) to create 788-812. Puta-
tive E2F sites were deleted with E2Fp27-900 (GAGGTCGCAGTCCGGAGC
GGTGGC) and E2Fp27-924 (CAGCTGGGCCAGTGAGCTCGGTACCTAT
CGATAGAGAAATG) to create 900-923. Finally, all three regions were
deleted with Foxp27-744 and E2Fp27-924. Mutated plasmids were ligated and
transformed into Escherichia coli. Plasmids were screened for the presence of a
newly created restriction site and sequenced.
Transfection and retrovirus transduction. Cells were transfected with
FuGENE 6 (Boehringer Mannheim) according to the manufacturer’s directions.
Recombinant retroviruses were generated as previously described (64) by trans-
fection of 293T cells with pBabe, wild-type LMP1 or mutant LMP1 plasmids, and
VSV-G (pG1-VSV-G)- and gag-pol (pGPZ9)-expressing plasmids. After 24 h
medium was changed and cells were incubated at 33°C overnight. The following
day culture supernatants were harvested and centrifuged at 1,000  g for 10 min
to remove cells and cellular debris. Rat-1 cells were transduced with clarified
293T culture supernatants overnight with 8 g/ml Polybrene (Sigma).
Cell culture and stable cell lines. Cell lines were maintained in Dulbecco
modified Eagle medium (Gibco) supplemented with antibiotic-antimycotic mix-
ture and 10% (vol/vol) heat-inactivated fetal bovine serum. Rat-1 rodent fibro-
blast stable cell lines were established by transduction with retrovirus and selec-
tion with puromycin (1 g/ml; Sigma). Transient selection for p27 expression was
accomplished by selection 24 h posttransfection with G418 (500 g/ml; Mediat-
ech) for 48 h.
RPA. RNase protection assays (RPAs) were performed using a Direct Protect
Lysate RPA kit (Ambion) according to the manufacturer’s directions as previ-
ously described (17). Briefly, RPA probes were annealed with RNA overnight in
lysis buffer. The following day samples were digested with RNase and protease
and precipitated. Protected probes were resolved on a 5% polyacrylamide gel,
dried, and imaged using a PhosphorImager (Molecular Dynamics). Bands were
quantitated using ImageQuant 5.1 (Molecular Dynamics), and p27 RNA levels
were determined relative to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) levels.
Cell harvesting and Western blotting. Cell lines were grown in 100-mm tissue
culture plates to confluence and harvested. Cells were washed with ice-cold
phosphate-buffered saline (Gibco) and lysed with 100 to 250 l RIPA buffer (10
mM Tris-HCl, pH 8.0, 140 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl
sulfate [SDS], 1% deoxycholic acid, protease and phosphatase inhibitors
[Pierce]). Cell lysates were clarified by centrifugation and quantitated by Bio-
Rad DC protein assay system (Bio-Rad). Samples were then boiled in SDS
sample buffer, and indicated amounts of protein were separated using 12%
acrylamide SDS-polyacrylamide gel electrophoresis and transferred to nitrocel-
lulose membranes (Li-Cor) for Western blotting analysis. Primary antibodies
included actin and hemagglutinin (HA) tag (Cell Signaling), LMP1-specific an-
tibodies (Cao 7E10, Cao 8G3, LMP1 IG6, and Cao 7G8; Ascenion GmbH), p27
(Santa Cruz), and myc tag (Upstate). LMP1 antibodies were detected with
biotinylated anti-rat immunoglobulin G (heavy plus light) (16-16-12; Kirkegaard
& Perry Laboratories, Inc.) followed by reaction with IRDye 680-labeled strepta-
vidin (Li-Cor). Other bound proteins were detected with IRDye-labeled second-
ary antibodies by scanning with a Li-Cor Odyssey imaging system. Bands were
quantitated using the Li-Cor imaging software.
p27 promoter luciferase assays. Promoter reporter assays were performed as
previously described (17). 293T cells were plated 1:5 into 12-well plates 1 day
prior to transfection. Cells were transfected with 0.2 g of pRL-SV40 (Renilla
luciferase) (Promega), 0.2 g of pGL3-Basic or p27 promoter plasmids, and 0.2
g of pBabe or LMP1-expressing plasmids. The following day the medium was
changed, and 40 h posttransfection cells were harvested and luciferase activity
was assayed using the dual-luciferase reporter assay system (Promega) according
to the manufacturer’s directions. Relative luciferase activity was determined by
dividing the firefly luciferase activity of the p27 promoter constructs by the
internal control Renilla luciferase activity. Each condition was used in triplicate
and replicated in different experiments.
EMSA. Approximately 5  107 cells were trypsinized, washed with ice-cold
phosphate-buffered saline, and pelleted. Cell pellets were resuspended in 350 l
buffer A (20 mM HEPES, pH 7.5, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA,
1 mM dithiothreitol, and protease and phosphatase inhibitors [Pierce]) and
incubated on ice for 15 minutes. Cells were lysed by addition of NP-40 (1% final
concentration) followed by vortexing for 1 minute. Nuclei were pelleted by
centrifugation at 1,000  g at 4°C for 10 minutes. The nuclear pellet was washed
one time in buffer A and solubilized by addition of 1 pellet volume of NE buffer
(20 mM Tris, pH 8.0, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25%
[vol/vol] glycerol), 1/4 pellet volume of 5 M NaCl, and 1 pellet volume of NE
buffer followed by vortexing. Clarified nuclear lysates were quantitated as above
and used for EMSA.
EMSAs were performed using the EMSA buffer kit for the Odyssey imaging
system (Li-Cor) according to the manufacturer’s directions. Shifts were per-
formed using 5 g of nuclear protein bound to labeled probes and were visual-
ized using a Li-Cor Odyssey imaging system. The IRDye 700 infrared dye-labeled
oligonucleotides (Integrated DNA Technologies) contained the putative E2F
sites of the rat p27KIP1 promoter (CCCTGGGTTTCGCGGGCAAAGACC
TGG, forward strand consensus underlined and reverse strand consensus in bold
and italics). Competition reactions were performed with a 200-fold molar excess
of unlabeled consensus probe (ATTTAAGTTTCGCGCCCTTTCTCAA, con-
sensus underlined) or mutated probe (ATTTAAGgggatataCCTTTCTCAA, mu-
tations in lowercase and underlined). Supershifts were performed by incubation
of nuclear lysates in binding buffer with antibodies for 20 min prior to probe
addition. Antibodies purchased from Santa Cruz used for supershifts included
p107 (sc-318 X), p130 (sc-317 X), Rb (sc-50 X), E2F1 (sc-251 X), E2F4 (sc-512
X), and DP1 (sc-610 X).
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RESULTS
In this study, the mechanism of p27 downregulation by
LMP1 was determined using LMP1 mutants that differ in their
abilities to activate different signaling pathways and induce
transformation. LMP1 mutants used in this study include full-
length LMP1 in which the TRAF binding domain is mutated to
all alanines (LMP1-A5) (mutated CTAR1/wild-type CTAR2),
1-220 (wild-type CTAR1/truncated at amino acid 220 and de-
letion of CTAR2), and 1-220-A5 (mutated CTAR1/deletion of
CTAR2). We have previously shown that LMP1 and 1-220 can
transform Rat-1 cells, activate MEK/ERK signaling, and reg-
ulate cell cycle markers p27, Cdk2, and Rb. LMP1-A5 is not
transforming and does not activate MEK/ERK signaling but
still regulates cell cycle markers. 1-220-A5 is not transforming
and does not regulate cell cycle proteins. The mechanism of
downregulation of p27 by LMP1 is unknown.
Effects of LMP1 on p27 protein. To determine the effects of
LMP1 and LMP1 mutants on p27 protein levels, stable cell
lines were examined. Rat-1 cells were stably transduced with
control (Babe)-, LMP1-, and LMP1 mutant-expressing retro-
virus. Cells were grown to confluence, harvested, and then
examined by Western blotting for p27 protein levels (Fig. 1).
p27 levels were quantitated relative to actin loading control,
and LMP1 and LMP1 mutant expression was confirmed by
detection of the HA tag. Full-length LMP1 and LMP1-A5 at
about 66 kDa were detected with a typical degradation product
at about 35 kDa. 1-220 and 1-220-A5 LMP1 mutants were
detected at about 30 kDa. Expression of CTAR1-containing
constructs, LMP1 and 1-220, was less than LMP1-A5 and
1-220-A5 expression. Lower LMP1 and 1-220 expression is
consistent with increased ubiquitination and proteasomal deg-
radation mediated by CTAR1-TRAF binding and consistent
with previous expression of these mutants (44, 62). In agree-
ment with our previous studies, the levels of p27 protein were
decreased to approximately 30% of control p27 levels (17, 18,
43–45). The full-length LMP1 mutant with CTAR1 mutated,
LMP1-A5, and 1-220 (CTAR2 deleted) also decreased p27
protein to approximately half that of control cell lines while the
truncated CTAR1/CTAR2 mutant, 1-220-A5, had minimal ef-
fect on p27 protein levels.
We had previously determined that LMP1 decreased p27
RNA and p27 promoter reporter activity (17). However, p27 is
frequently regulated at the posttranscriptional level during
cancer development and in cancer cells. LMP1 has been shown
to induce proteasome-mediated protein degradation through
effects on kinase activation, ubiquitination, and deubiquitina-
tion. To determine if LMP1 also affects p27 protein levels,
subconfluent Rat-1 control and LMP1 stable cell lines were
transfected with vector control (DNA3) or myc-tagged p27
plasmid. Transfected cells were selected 24 h posttransfection
with G418 for 24 h and harvested. Western blotting was per-
formed for LMP1 and p27 (Fig. 2). Expression of LMP1 and
myc-tagged p27 was confirmed. The myc-tagged p27 (upper
arrow) was distinguished from endogenous p27 (lower arrow)
by the increase in molecular mass of about 5 kDa due to the
tandem triple myc tag and confirmed by Western blotting with
myc tag antibody. In agreement with previous unpublished
observations, endogenous p27 was barely detectable in subcon-
fluent Rat-1 cells. The levels of the exogenous myc-p27 were
equivalent in control and LMP1 stable cell lines. Equal loading
was confirmed by Ponceau S staining. These data indicate that
LMP1 does not affect p27 protein levels expressed from an
ectopic promoter and suggest that LMP1 does not regulate p27
expression by affecting protein stability.
Regulation of p27 RNA by LMP1 mutants. To assess the
effects of the LMP1 mutants on p27 transcription, RNA RPAs
were performed using confluent Rat-1 stable cell lines. RPAs
FIG. 1. Downregulation of p27 protein by LMP1 and LMP1 mu-
tants. Control (Babe) and wild-type and mutant LMP1 stable Rat-1
cells were assayed by Western blotting for p27 compared to actin
(loading control). Expression of tagged LMP1 constructs was con-
firmed with HA antibodies. p27 expression was quantitated relative to
actin levels using the Li-Cor Odyssey imaging system and indicated as
a value relative to Babe cells set as 100. The positions of the molecular
weight markers (in thousands) are indicated by the closed arrowheads.
FIG. 2. Regulation of ectopic p27. The ability of LMP1 to post-
transcriptionally regulate ectopically expressed p27 was determined.
Control and LMP1 stable cell lines were transfected with myc-tagged
p27 and selected for 48 h with G418. Cell lysates from control (Babe)
or LMP1 stable cells transfected with vector (DNA3) or p27-express-
ing plasmids were analyzed by Western blotting for p27 and LMP1
expression. A 7.5-g amount of protein was loaded per lane. The
positions of myc-tagged and endogenous p27 proteins are indicated by
the arrows. The positions of the molecular weight markers (in thou-
sands) are indicated by the closed arrowheads.
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were performed, and values were normalized to that of the
housekeeping gene GAPDH. The mean p27/GAPDH expres-
sion levels were determined from three independent experi-
ments (Fig. 3). LMP1 reduced p27 RNA to approximately 40%
of control p27 levels (17). In LMP1-A5- and 1-220-expressing
cells, p27 RNA was reduced to about 40 to 50% of control
levels. Surprisingly, p27 RNA was also decreased about 50%
with the CTAR1/CTAR2 double mutant 1-220-A5 It is un-
known how this doubly deleted LMP1 could affect transcrip-
tion. However, this nontransforming LMP1 minimally de-
creased the levels of p27 protein (92% in Fig. 1). These data
indicate that LMP1 decreases p27 RNA and that this ability is
linked to transformation.
Regulation of the p27KIP1 promoter by LMP1. To assess the
ability of LMP1 and LMP1 mutants to regulate the p27 pro-
moter, promoter reporter assays were performed. 293T cells
were cotransfected with the empty reporter vector (pGL3-
Basic) or p27 reporter (p27-1501), transfection control Renilla
luciferase, and effector plasmids, encoding LMP1 or LMP1
mutants. Full-length p27 promoter activity was plotted relative
to the internal control Renilla luciferase activity (Fig. 4A). In
agreement with our previous study (17), LMP1 greatly de-
creased the activity of the p27 promoter reporter plasmid,
indicating that LMP1 regulates the p27KIP1 promoter.
LMP1-A5 and 1-220 were slightly impaired compared to wild-
type LMP1 in their ability to decrease the promoter activity,
and the double mutant, 1-220-A5, reduced the promoter ac-
tivity by about 30%. Other previously described CTAR1/
CTAR2 mutants (44), including 1-208-A5, A5-Y384G, and
A5-378stop, also reduced promoter activity by about one-third
(data not shown). In parallel, cells were harvested for Western
blotting for LMP1 expression (Fig. 4B). Wild-type LMP1 and
LMP1 mutants were equally expressed in the reporter assays as
determined by blotting with LMP1 and HA tag. Equal loading
was confirmed by actin blotting. These data indicate that
LMP1 and LMP mutants containing CTAR1 negatively regu-
late the p27KIP1 promoter similarly to the p27 protein levels
while LMP1 mutants lacking CTAR1 and CTAR2 slightly re-
duce p27 RNA and promoter activity that may not be reflected
in the protein levels.
Previous studies indicated that LMP1 induces two members
of the Id family of proteins, Id1 and Id3 (18). The Id proteins
are known to inhibit the expression of CDKIs p16 and p21 at
the transcriptional level (55, 59, 87). However, we have re-
cently determined that Id1 and/or Id3 overexpression does not
regulate p27 RNA or p27 promoter reporter activity (17). This
indicates that LMP1 decreases p27 transcription indepen-
dently from its induction of Id1 and Id3 expression. To map the
cis elements required for LMP1 regulation, the promoter was
truncated at convenient restriction sites (Fig. 5A). LMP1 and
LMP1 mutants were tested for their ability to downregulate
p27-554, containing 554 bp of the p27 promoter (Fig. 4A). The
reporter p27-554 had little activity in the promoter assay, sug-
gesting that the majority of the activating regions of the p27
promoter were located between bp 555 and 1501. Trunca-
tions containing 1,066 (p27-1066) and 939 (p27-939) bp were
tested against wild-type LMP1 (Fig. 5B). Since each mutated
reporter had slightly different intrinsic activity (Fig. 5B), the
activity of each reporter in the presence of LMP1 was normal-
FIG. 3. Regulation of p27 RNA by LMP1 mutants. RPAs were
performed using total RNA from stable cell lines. Fragments protected
by rat p27KIP1 RNA probe relative to control (GAPDH) RNA probe
were quantitated using a PhosphorImager, and p27 expression is de-
picted relative to that in control (Babe) stable cells, which was set
arbitrarily as 100. Means of three independent experiments are pre-
sented with error bars representing the standard deviations.
FIG. 4. Regulation of the p27KIP promoter by LMP1 mutants.
Promoter reporter assays were performed by transfection of 293T cells
with control pRL-SV40 with pGL3-Basic (empty reporter) or p27
(p27-1501 and p27-554) reporter plasmids and vector control (Babe)
or plasmids expressing LMP1 (A). p27 promoter plasmids contain
1,500 and 554 bp of the Rattus norvegicus p27KIP1 promoter relative to
the translation start site. Forty hours posttransfection, cells were har-
vested and dual-luciferase assays were performed. Relative luciferase
activity was determined by the firefly luciferase activity of the reporter
constructs relative to the control Renilla luciferase activity. Each con-
dition was used in triplicate, and the means of three independent
experiments are presented. Error bars represent the standard devia-
tions from the independent experiments. In parallel, cells were har-
vested for Western blotting (B). Levels of wild-type LMP1 and LMP1
mutants were determined by blotting for LMP1 and HA tag. Actin
blotting confirmed equal loading. The positions of the molecular
weight markers (in thousands) are indicated.
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ized to the activity of the reporter with the Babe vector control
(Fig. 5C). Both p27-1066 and p27-939 had approximately the
same activity as that of the full-length construct and were each
inhibited by LMP1 to approximately one-fourth the activity of
control reporter (Fig. 5C). This suggests that the region regu-
lated by LMP1 is between 555 and 939 within the p27
promoter.
To determine potential transcription factor binding sites
within the region between 555 and 939 of the p27 pro-
moter, online programs, including TFSEARCH and Motif-
Mogul (24, 27), were used to identify putative cis elements.
Three potential elements were predicted by more than one
program: a forkhead (FOX0) transcription factor family bind-
ing site at approximately 750 bp, an MZF1 site at 800 bp,
and two E2F sites at approximately 910 bp. PCR primers that
flanked the predicted sites were designed, and PCR mutagen-
esis was performed to delete the putative binding sites (Fig.
5A). Specific sites were deleted in the p27-939 reporter indi-
vidually: 740-774 deleted the FOX0 site, 788-812 deleted
the MZF1 site, and 900-923 deleted the E2F sites. Finally the
extreme 5 and 3 primers were used to delete all three sites
from 740 to 923 (740-923).
Promoter reporter assays were performed with the mutated
reporter constructs to identify the cis elements of the p27KIP1
promoter regulated by LMP1. The mutant lacking the FOX0
sites (740-774) had approximately the same activity as that of
p27-939 and was downregulated by 75 to 80% by LMP1. How-
ever, mutation of the E2F sites (900-923) increased the over-
all activity of the construct and was only slightly inhibited by
LMP1 (Fig. 5B and C). The requirement for this region was
confirmed with the mutant having a deletion of the entire
region from 740 to 923 (740-923), and the inhibition by
LMP1 was impaired (Fig. 5B and C, respectively). Interest-
ingly, this promoter had approximately twice the activity of
p27-939 in control cells (Fig. 5B), indicating that the sequences
between bp 923 and 939 that contain the E2F sites negatively
regulate transcription in the absence of LMP1. Deletion of the
predicted MZF1 (788-812) site resulted in complete loss of
promoter activity regardless of the presence or absence of
LMP1. To ensure that the MZF1 mutant promoter reporter
did not contain other mutations that resulted in the loss of
activity, the region containing the deletion was subcloned into
a new reporter and the site-directed mutagenesis was per-
formed again on a new parental plasmid. Both new constructs
also lacked promoter activity (data not shown). The reason for
the lack of activity of this construct is unclear and was inde-
pendent of the presence of LMP1. These data indicate that the
p27 promoter is negatively regulated by an element between
900 and 923 bp of the promoter and that this negative
regulation is greatly enhanced by LMP1.
Both of the transcription factor binding site algorithms pre-
dicted two E2F sites within the 900 to 923 region of the p27
promoter (Fig. 6A). The E2F consensus sequence of TTC
GCGC is present in both the forward and reverse orientations
in an overlapping element. If this element is important for p27
regulation, then it should be conserved among different spe-
cies. The p27 promoters of both rat and mouse are entirely
conserved at approximately the same position. The E2F-like
elements were less conserved in the human p27 promoter but
were located at the same relative position as those of the rat
and mouse promoters.
To determine if LMP1 regulates E2F DNA binding com-
plexes, EMSAs were performed using nuclear lysates from
fractionated control and stable cell lines. Labeled probes cor-
responding to the E2F sites of the rat p27 promoter were used
(Fig. 6A). Shifted probe was detected in both control (Babe)
and LMP1 lysates, suggesting that there are multiple shifted
complexes (Fig. 6B, lanes 2 and 3). The unshifted probe was
barely detectable, suggesting that many forms of E2F can bind
the probe and alter its mobility (lane 1). In all experiments, the
complexes from LMP1-expressing cells were more intense and
migrated in a broader band. This suggests that LMP1 induces
more proteins that are able to bind to these sequences. Both
the lower and higher complexes were competed with oligonu-
cleotides containing a consensus E2F site (LMP1comp, lane
4) but not mutated E2F consensus (LMP1mutant, lane 5).
These data confirm that LMP1 increases proteins that bind an
E2F site.
To identify specific proteins bound to the probe, the com-
FIG. 5. Mutation of cis-acting elements within the p27 promoter.
Computer-based algorithms were used to identify putative transcrip-
tion factor binding sites within the region from 554 to 939 of the
p27KIP1 promoter. (A) Putative sites were deleted by PCR to mutate
the indicated bases and transcription factor binding sites individually
or together. (B) Promoter reporter assays were performed as described
for Fig. 4 except that only control (Babe) and LMP1 were used as
effector plasmids. (C) Promoter activity of deleted reporters from
panel B is depicted relative to activity of the reporter of the control
(Babe) effector set to 100.
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plexes were treated with antibodies to the predicted transcrip-
tion factors to produce antibody-supershifted complexes. The
E2F proteins are a family of transcription factors. E2F1, E2F2,
and E2F3a act as activators and are repressed by hypophos-
phorylated Rb protein. LMP1 induces increased hyperphos-
phorylated Rb in transformed fibroblasts and tumors from
LMP1 transgenic mice (18, 43, 44, 65). Antibody to Rb did not
alter the migration of the LMP1-induced complexes (Fig. 6B,
lanes 14 and 15), nor did antibody to E2F1 affect the com-
plexes (data not shown).
E2F3b and E2F4-E2F7 act as repressors, and the site
present in the rat and mouse promoter closely resembles a
consensus defined by hidden Markov modeling (47, 48) for
E2F4-DP1 binding, TTCGCGCGAA (Fig. 6A). To determine
if E2F4 and DP1 were present in the LMP1-induced com-
plexes, E2F4 and DP1 antibodies were included in the EMSA
reaction mixtures. E2F4 antibody induced a shifted complex
that was increased in the LMP1 sample (Fig. 6B, lanes 6 and
7). Altered shifted complexes were not detected with the DP1
antibody in LMP1 cells (lanes 8 and 9). To repress transcrip-
tion, E2F4 binds the pocket protein p107 or p130. Antibody
supershifts were performed to determine if p107 or p130 was
present in the EMSA complexes. A distinct supershifted band
was produced with the p130 antibody, and this complex was
considerably more prominent in the LMP1 samples (lanes 10
and 11). Antibody to p107 did not affect the migration of any
bands (lanes 12 and 13). The data indicate that LMP1 induces
binding of the repressive E2F4 and p130 to the predicted E2F
site within the p27 promoter.
DISCUSSION
The data presented in this study define the mechanism of
p27 downregulation by LMP1. We have previously shown that
several cell cycle markers are affected by LMP1 in fibroblast
transformation assays: p27 was decreased, Cdk2 was increased
and activated, and Rb was increased and hyperphosphorylated.
These same effects have been detected in the tumors of LMP1
transgenic mice and in EBV-transformed cells.
Cell cycle progression is controlled by the activity of cyclins,
CDKs, and CDKIs. As a result of this potent growth-inhibitory
activity, CDKIs are frequently nonfunctional in many cancers
possibly through deletion or mutation (2, 4, 76). Interestingly,
during cancer development and in cancer cells p27 is regulated
posttranscriptionally and can be degraded or sequestered in
the cytoplasm in cancers of the colon, prostate, esophagus,
thyroid, ovary, and breast (6, 10, 23, 25, 42, 49, 67, 69, 75).
However, in the present study ectopically expressed p27 was
not decreased in LMP1-expressing cells. Also, levels of p27
RNA and activity of promoter reporters were decreased to the
same extent as p27 protein levels in the presence of LMP1.
Together these data indicate that LMP1 primarily affects p27
expression at the transcriptional level. In addition, the data
suggest that p27 transcription is decreased in EBV-trans-
formed cells due to effects on E2F and p130 pocket protein
function.
Previous LMP1 mutational analyses indicated that activation
of PI3K-Akt signaling by LMP1 is required for transformation,
and this correlated with the effects of LMP1 on the cell cycle
markers p27, Cdk2, and Rb (43, 44). A target of Akt signaling
is the forkhead family of transcription factors, and both LMP1
and LMP2 can regulate forkhead transcription factors (68).
FOXA1 in conjunction with BRCA1 has been shown to regu-
late p27 in breast cancer cells (79, 80), and other forkhead
family members also regulate p27 transcription (9, 50, 54).
Although the putative FOXA1/BRCA1 site is almost entirely
conserved between human and rat p27 promoters, the deletion
of the FOXA1/BRCA1 site did not affect the decrease in p27
promoter activity by LMP1. In contrast, deletion of the E2F
site of the promoter greatly increased baseline promoter func-
tion and decreased its inhibition by LMP1 Deletion of the
entire region within the promoter had activity similar to that of
the E2F deletion alone, suggesting that synergy between E2F
factors and forkhead transcription factors is unlikely. Impor-
tantly, these data indicate that negative transcriptional regula-
tion of p27 is mediated by members of the E2F family, likely
E2F4.
The identified E2F site in the current study is completely
conserved between the mouse and rat p27 promoters, and a
similar site was observed in the human p27 promoter. The
current study examined activity of the rat promoter reporter
within human 293T cells. The conservation of sequence and
position is suggestive of conserved regulation. Expression of
p27 is repressed in other model systems, like LMP1 transgenic
mice, and in EBV-transformed cells. Our study would suggest
that E2F4 represses the expression of p27 tumors of LMP1
FIG. 6. E2F EMSAs. (A) The positions, directions, and sequences
of the putative E2F sites of the rat, mouse, and human p27KIP1
promoters are depicted. The sequences of consensus E2F and E2F4-
DP1 sites are indicated. The forward consensus sites are indicated by
underlining, and the reverse consensus sites are indicated by bold and
italics. Base pair numbers are relative to the translation start site for
the p27 protein. (B) EMSAs using control (Babe) and LMP1 nuclear
lysates were performed. Complexes were competed with a 200-fold
excess of consensus (comp) and mutant oligonucleotides. Supershifts
with the indicated antibodies were performed. The arrow indicates the
position of nonspecific complexes, and boxes highlight the positions of
specific complexes. Arrowheads indicate the positions of the antibody-
shifted complexes for E2F4 (closed arrowhead) and p130 (open ar-
rowhead). Lane numbers are indicated below.
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transgenic mice. Future studies will more fully elucidate the
regulation of p27 in human cells expressing LMP1 or trans-
formed by EBV.
The p27 promoter deletions are also suggestive of positive
regulatory elements. Promoter reporter constructs containing
only 554 bp had much less activity than did constructs contain-
ing 939 bp. Surprisingly, the deletion of the sequence from
bp 788 to 812 abrogated the promoter activity completely while
the larger deletion of bp 740 to 923 had increased activity and
activity similar to that of the bp 900 to 923 deletion alone. It is
unclear why the promoter was inactivated by this smaller de-
letion of bp 788 to 812. Perhaps the newly juxtaposed se-
quences created a new site that blocked the recruitment of the
normal transcriptional machinery. However, the promoter
analyses do indicate that the E2F site negatively regulates the
activity of the promoter and that elements between bp 554 and
740 are required for normal or baseline promoter activity.
Deletion of the E2F site resulted in increased promoter
activity of the p27 promoter. E2F deletion reporters were re-
duced by only 25% by LMP1 as opposed to the 75 to 80%
reduction for reporters containing the E2F sites. The slight
reduction in the reporter in the absence of the E2F site could
indicate that multiple factors could be involved in LMP1-in-
duced p27 repression. A recent study has indicated that sur-
rounding sites can influence which E2F factors are recruited to
specific promoters (21). These other factors could be respon-
sible for recruitment of repressive E2Fs like E2F4 to the p27
promoter.
Several CTAR1/CTAR2 mutants do not significantly alter
p27 protein levels, including 1-220-A5, 1-208-A5, Y384G-A5,
378stop-A5, and 1-231-A5 (current study and reference 44).
Each of these mutants reduces p27 RNA levels (1-220-A5, Fig.
3) and p27 reporter activity (1-220-A5, Fig. 4, and others’
unpublished observations). Despite the decreased p27 RNA
levels and p27 reporter activity, the p27 protein levels remain
unchanged. The half-life of p27 protein has been measured to
be between 2 and 6 h in actively dividing cells and close to 10
to 12 h in quiescent or arrested cells (38, 46). The discrepancy
between p27 protein and RNA levels in cells expressing
CTAR1/CTAR2 mutants likely reflects the increased stability
of p27 in the contact-inhibited cells.
The EBV proteins LMP1 and EBNA3C regulate similar cell
cycle pathways via distinct mechanisms. In the current study
LMP1 regulates transcription of p27 RNA while EBNA3C
binds Rb in vitro and can cooperate with other oncogenes to
induce transformation (57). EBNA3C can also recruit the
SCFSkp2 ubiquitin-ligase complex to induce the degradation of
both p27 and Rb (36, 37) and block Cdk2/cyclin A-p27 binding
to stimulate Cdk2/cyclin A kinase activity (35). Targeting of the
cell cycle proteins by different mechanisms suggests the impor-
tance of these pathways for EBV-induced transformation and
defines mechanisms by which EBV can contribute to malignant
transformation.
Typical cell cycle models depict p27 blocking Cdk2 activity,
Cdk2 activity targeting Rb for phosphorylation and release of
E2F, and E2F transcription enabling cell cycle progression.
The findings in the current study suggest that there is a regu-
latory loop by which p27 expression is negatively regulated
by E2F function in LMP1-transformed cells. Several high-
throughput screens have found that overexpression of E2F1
leads to increased p27 expression in several different cell lines
(26, 29, 77). The most recent of those reports found that
addition of serum or overexpression of PI3K blocked E2F1-
dependent p27 induction and that the serum effect was blocked
by a PI3K inhibitor, LY294002 (26). These data indicate that
activation of PI3K signaling negatively regulates p27 transcrip-
tion. Our previous LMP1 mutational analysis also showed that
activation of PI3K signaling correlated with the ability to in-
hibit p27 expression (43, 44). The previous studies linking
E2F1 and increased p27 transcription found E2F1 expressed
exogenously to high levels. The data presented here demon-
strate binding of an endogenous E2F transcription factor to a
specific site in the p27 promoter and suggest that a repressive
E2F, E2F4, is recruited to the promoter with the pocket pro-
tein p130 to repress p27 transcription. This E2F4/p130 com-
plex may be replaced by an E2F1-containing complex when the
promoter is activated, or other factors may also regulate the
p27 promoter. Although LMP1 is known to downregulate nu-
merous proteins, the current study is the first to define a re-
pressive transcription complex.
Many studies have demonstrated multiple functions for p27
during the cell cycle (reviewed in reference 1). Although p27
functions as a tumor suppressor by inhibiting Cdk2 complexes,
it also stimulates the assembly of Cdk4/and Cdk6/cyclin com-
plexes. Knockout studies confirm an important role for p27
function. In some experimental systems p27/ mice have a
higher tumor incidence than do p27/ mice. It is unclear
whether reduced p27 as a result of LMP1 signaling alters
normal cell cycle control that might result in increased
genomic instability which could contribute to EBV-associated
cancers.
The current study also has implications for the development
of EBV-associated cancers. Both the Rb and p53 tumor sup-
pressor pathways are almost always deregulated during malig-
nant transformation. Other DNA tumor viruses encode pro-
teins that regulate these critical pathways (41). Polyomavirus
large T antigen, papillomavirus E7, and adenovirus E1A each
regulate Rb function and S-phase entry. Polyomavirus large T
antigen and papillomavirus E6 regulate p53 function. In these
tumors, p53 and Rb are not mutated and their deregulation
reflects the activity of the viral oncoproteins. The latency-
associated nuclear antigen of Kaposi’s sarcoma-associated her-
pesvirus also binds both p53 and Rb (74). In EBV-associated
tumors Rb and p53 are not mutated, suggesting that EBV
deregulates both the Rb and p53 pathways (15, 70). LMP1
specifically inhibits p53-mediated apoptosis through induction
of the expression of A20 (22). NF-B activity induced by LMP1
also blocks apoptosis, and inhibition of NF-B activity induces
apoptosis of EBV-transformed lymphocyte cell lines (7, 8). In
a recent study inhibition of MDM2-dependent p53 degrada-
tion induced apoptosis of EBV-infected cells that was en-
hanced by NF-B inhibition (19). Another EBV protein,
EBNA3C, has recently been reported to bind and regulate
both p53 and MDM2 (63, 82). The current study suggests that
LMP1 regulates the Rb pathway through effects on p27 to
stimulate cell cycle progression. Regulation of the Rb and p53
tumor suppressor pathways by LMP1 and/or EBNA3C likely
contributes to EBV-induced transformation and to the devel-
opment of EBV-associated malignancies.
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